|
answer text |
<p>From April 2020 a new National Health Service CQUIN (Commissioning for Quality
and Innovation framework) will be introduced to support early identification of cirrhosis
and enhanced fibrosis in alcohol dependent individuals. The CQUIN will incentivise
acute and mental health providers to ensure that appropriate tests (transient elastography,
enhanced liver fibrosis or STLT blood tests) are carried out on in-patients who have
a diagnosis of alcohol dependence.</p><p>The delivery of the national CQUIN to support
early identification of cirrhosis and enhanced fibrosis against a standard set of
criteria will support tackling regional variation.</p><p>Specialised commissioning
is also supporting a programme to identify people with hepatitis C infection at an
early stage to avoid subsequent liver disease.</p><p>In 2019/20, Public Health England
(PHE) awarded £6 million capital funding to 23 local authorities to support their
ambitions to increase access to alcohol treatment. This includes supporting nine areas
to purchase fibroscan machines to increase early detection and access to treatment
for those with alcohol-related liver disease.</p><p>PHE is also supporting work to
increase opportunities for the earlier detection of alcohol-related liver disease
in people drinking at or above high-risk levels. This includes new NHS Health Check
guidance to encourage referral for liver investigation.</p><p>Additionally, the rollout
of optimal Alcohol Care Teams across England in the areas with the highest rates of
alcohol dependence-related admissions will improve the care pathway, including the
use of appropriate diagnostics, for patients and their families who have issues with
alcohol dependence.</p><p> </p><p> </p>
|
|